NPY and Alzheimer disease: Moreover, our study suggests that at early stages of AD-related pathology, GABAergic neurons downregulate at least some of their neurochemical markers (PV, NPY) but remain present, as no neuronal loss was detected by stereological quantification of NeuN-IR cells.